Price$79.39-0.90 (-1.12%)
01:30 PM07:45 PM
News · 26 weeks62+300%
2026-04-192026-10-11
Mix2990d
- Insider13(45%)
- SEC Filings5(17%)
- Other5(17%)
- Earnings2(7%)
- Leadership2(7%)
- Analyst2(7%)
Latest news
25 items- ANALYSTGoldman initiated coverage on Zoetis with a new price targetGoldman initiated coverage of Zoetis with a rating of Neutral and set a new price target of $74.00
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Zoetis Inc.4 - Zoetis Inc. (0001555280) (Issuer)
- SECSEC Form 8-K filed by Zoetis Inc.8-K - Zoetis Inc. (0001555280) (Filer)
- PRZoetis Appoints Iris Knobloch to its Board of DirectorsKnobloch brings deep expertise in consumer strategy, digital transformation, international leadership, and global board experience to the Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience across global media and consumer businesses, Ms. Knobloch brings a distinct combination of international leadership, proven public company board experience across financial services, hospitality and media, and deep consumer and digital expertise to the Zoetis Board. She currently serves on the boards of Deezer S.A., Lazard, Inc. and Vail Resorts, Inc., and has built a track record of
- SECSEC Form 8-K filed by Zoetis Inc.8-K - Zoetis Inc. (0001555280) (Filer)
- PRZoetis Declares Fourth Quarter 2026 DividendThe Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company’s common stock as of the close of business on Friday, October 30, 2026. About Zoetis Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness supporting veterinarians, livestock producers and pet owners in over 100 countries. We integrate deep scientific experti
- PRNew Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1Findings highlight dose-dependent efficacy of moxidectin in preventing heartworm disease Published Data Demonstrated: Simparica Trio®-treated dogs had significantly lower average heartworm counts than NexGard Plus-treated dogs (P = 0.0316).1 Simparica Trio delivered 99.5% efficacy against macrocyclic lactone (ML)-resistant heartworm isolate, ZoeLA, compared to 98.1% for NexGard Plus.1 Simparica Trio protected more dogs from infection: Adult heartworms were found in just 2/8 (25%) of dogs treated with Simparica Trio, versus 6/8 (75%) of dogs treated with NexGard Plus.1 No detection of circulating heartworm offspring (microfilariae) in Simparica Trio-treated dogs: None of the Si
- INSIDERExecutive Vice President Fuller Julie converted options into 799 shares and covered exercise/tax liability with 274 shares, increasing direct ownership by 49% to 1,588 units (SEC Form 4)4 - Zoetis Inc. (0001555280) (Issuer)
- PRZoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial ResultsZoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay Saccaro will review third quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay will be made available on November 5, 2026. About Zoetis Zoetis is the world’s leading animal health company, driven by
- INSIDERSEC Form 4 filed by Director Stetter Mark4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by EVP, CFO & COO Saccaro James4 - Zoetis Inc. (0001555280) (Issuer)
- PRZoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceZoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET. Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a l
- INSIDERNew insider Saccaro James claimed no ownership of stock in the company (SEC Form 3)3 - Zoetis Inc. (0001555280) (Issuer)
- PRZoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and PuppiesExpands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax, commonly called New World screwworm (NWS), feed on living
- INSIDERDirector Damelio Frank A gifted 6,650 shares, decreasing direct ownership by 31% to 14,808 units (SEC Form 4)4 - Zoetis Inc. (0001555280) (Issuer)
- SECSEC Form 8-K filed by Zoetis Inc.8-K - Zoetis Inc. (0001555280) (Filer)
- SECSEC Form 10-Q filed by Zoetis Inc.10-Q - Zoetis Inc. (0001555280) (Filer)
- ANALYSTZoetis downgraded by William BlairWilliam Blair downgraded Zoetis from Outperform to Mkt Perform
ZTS FAQ
8 questionsWhat does Zoetis Inc. do?
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria...Where does ZTS stock trade?
Zoetis Inc. (ZTS) is listed on NYSE.What sector and industry is ZTS in?
Zoetis Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zoetis Inc. go public?
Zoetis Inc. (ZTS) completed its IPO in 2013.Does ZTS pay a dividend?
Yes. ZTS's next ex-dividend date is 2026-10-30 with a declared cash dividend of $0.53 per share, payable 2026-12-01.What are analysts saying about ZTS?
Zoetis Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Neutral on 2026-10-16.What companies are similar to ZTS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ZTS side-by-side with any of them on Quantisnow.How can I track ZTS on Quantisnow?
Quantisnow aggregates Zoetis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZTS to receive live email and push alerts on every new disclosure.